Propel mometasone furoate implant

From LIMSWiki
Jump to navigationJump to search

Steroid-eluting sinus stents may be used in addition to endoscopic sinus surgery. They are, however, of unclear benefit as of 2015.[1]

One version releases mometasone furoate. It is a bioabsorbable steroid-eluting stent. It delivers steroids over a 30-day period prior to dissolving.[2]

Society and culture

A number of brands exist including Relieva Stratus Spacer and Propel sinus implant.[3][4]

Approval

One brand received pre-market approval from the FDA in 2011.

References

  1. ^ Huang, Z; Hwang, P; Sun, Y; Zhou, B (10 June 2015). "Steroid-eluting sinus stents for improving symptoms in chronic rhinosinusitis patients undergoing functional endoscopic sinus surgery". The Cochrane Database of Systematic Reviews (6): CD010436. doi:10.1002/14651858.CD010436.pub2. PMID 26068957.
  2. ^ Lee, Jivianne T; Han, Joseph K (2013). "Sinus implants for chronic rhinosinusitis: Technology evaluation". Expert Opinion on Drug Delivery. 10 (12): 1735–48. doi:10.1517/17425247.2013.839654. PMID 24088141. S2CID 22761647.
  3. ^ Liang, Jonathan; Lane, Andrew P. (2012). "Topical Drug Delivery for Chronic Rhinosinusitis". Current Otorhinolaryngology Reports. 1 (1): 51–60. doi:10.1007/s40136-012-0003-4. PMC 3603706. PMID 23525506.
  4. ^ Kennedy, David W (2012). "The PROPEL™ steroid-releasing bioabsorbable implant to improve outcomes of sinus surgery". Expert Review of Respiratory Medicine. 6 (5): 493–8. doi:10.1586/ers.12.53. PMID 23134241. S2CID 207223274.

Notes

This article is a direct transclusion of the Wikipedia article and therefore may not meet the same editing standards as LIMSwiki.